Kyntra Bio, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $30.4M
- Price
- $7.52
- % Change (Daily % change from the live per-ticker quote feed.)
- +2.73%
- Volume
- 40.0K
About
Kyntra Bio, Inc. functions as a biopharmaceutical enterprise, encompassing the entire process from the initial discovery and rigorous development of innovative treatments to their ultimate market introduction. The company's scientific focus delves into the complex biology of hypoxia-inducible factors (HIF) and connective tissue growth factors (CTGF). Through this research, Kyntra Bio strives to create groundbreaking therapies aimed at tackling conditions like anemia, various fibrotic disorders, and different forms of cancer. Established by Thomas B. Neff on September 29, 1993, the firm's main offices are situated in San Francisco, California.
Quick stats
Shares outstanding4.0M
Computed float3.9M
Float / shares95.7%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0000921299
Websitehttps://www.kyntrabio.com
AI Summary
AI-generated1/10
majorbullishearnings
Kyntra Bio Reports Second Quarter 2026 Financial Results and Provides Business Update
Kyntra Bio reported Q2 revenue of $(1.5) million compared to $1.3 million in the prior year, while net income swung to a profit of $12.0 million, or $2.96 per share, driven primarily by a $30.9 million gain on the deconsolidation of a subsidiary.
The company ended the quarter with $95.7 million in cash, equivalents, and receivables, which it expects will be sufficient to fund operating plans into 2028.
Operationally, management finalized the protocol for the pivotal Phase 3 trial of roxadustat in LR-MDS, targeting a 4Q 2026 initiation, and confirmed that the interim analysis for the Phase 2 FG-3246 trial in mCRPC remains on track for the same quarter.
Red flags
- Total revenue from continuing operations was negative $(1.5) million driven by drug product revenue net of reserves